SCHEMBL22245231

SCHEMBL22245231

CCOCCc1nn(C)c2c(=O)[nH]c(N(C)c3ccc(Cl)c(Cl)c3)nc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 12/20 0.40
KMT2A Q03164 2/20 0.40
PDE1A P54750 2/20 0.40
PDE1B Q01064 2/20 0.40
PDE1C Q14123 2/20 0.40
PDE6C P51160 2/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
MTOR P42345 1/20 0.40
POLB P06746 1/20 0.38
KDM4E B2RXH2 1/20 0.37
HDAC6 Q9UBN7 4/20 0.37
HDAC1 Q13547 3/20 0.37
PDE3B Q13370 2/20 0.37
PDE3A Q14432 2/20 0.37
HDAC2 Q92769 1/20 0.37
PDE2A O00408 1/20 0.37
ABCC4 O15439 1/20 0.37
ABCC5 O15440 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22119539 0.89 PDE5A (0.41) PDE5AKMT2APDE1APDE1BPDE1C
SCHEMBL22119384 0.80 PDE5A (0.34) PDE5AKMT2APDE1APDE1BPDE1C
SCHEMBL22245180 0.79 HDAC3 (0.32) HDAC6HDAC1HDAC2
SCHEMBL22245238 0.79 FPR2 (0.33) HDAC6HDAC1HDAC2
SCHEMBL22119562 0.78 HDAC1 (0.38) PDE5AKMT2AMEN1HDAC6HDAC1
SCHEMBL22119459 0.77
SCHEMBL22245190 0.77 TRPA1 (0.32) ALDH1A1KDM4EHDAC6HDAC1HDAC2
SCHEMBL4897820 0.74 PDE5A (0.49) PDE5AKMT2APDE1APDE1BPDE1C
SCHEMBL4902249 0.74 PDE5A (0.49) PDE5AKMT2APDE1APDE1BPDE1C
SCHEMBL22245155 0.74 RXRA (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12534470-B2 DNA polymerase IIIC inhibitors and use thereof Acurx Pharmaceuticals, Inc. (US) 2026-01-27 US disclosed
US-20230250102-A1 DNA Polymerase IIIC Inhibitors and Use Thereof Acurx Pharmaceuticals, Inc. 2023-08-10 US disclosed
US-11001592-B2 DNA polymerase IIIC inhibitors and use thereof ACURX PHARMACEUTICALS, LLC (US) 2021-05-11 US disclosed
US-10836772-B2 DNA polymerase IIIC inhibitors and use thereof ACURX PHARMACEUTICALS, LLC (US) 2020-11-17 US disclosed
US-20200308179-A1 DNA Polymerase IIIC Inhibitors and Use Thereof Acurx Pharmaceuticals, Inc. 2020-10-01 US disclosed
US-20200308180-A1 DNA Polymerase IIIC Inhibitors and Use Thereof Acurx Pharmaceuticals, Inc. 2020-10-01 US disclosed
US-10723741-B1 DNA polymerase IIIC inhibitors and use thereof ACURX PHARMACEUTICALS, LLC (US) 2020-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12534470-B2 DNA polymerase IIIC inhibitors and use thereof POLR1A, POLR2H, POLN PDE5A 3991/4885KMT2A 2397/4885PDE1A 4263/4885
US-20200308180-A1 DNA Polymerase IIIC Inhibitors and Use Thereof POLI, POLN, POLB PDE5A 1111/4885KMT2A 2315/4885PDE1A 2625/4885
US-20230250102-A1 DNA Polymerase IIIC Inhibitors and Use Thereof POLI, POLN, POLB PDE5A 1152/4885KMT2A 2290/4885PDE1A 2568/4885
US-20200308179-A1 DNA Polymerase IIIC Inhibitors and Use Thereof POLI, POLN, POLB PDE5A 1111/4885KMT2A 2315/4885PDE1A 2625/4885
US-11001592-B2 DNA polymerase IIIC inhibitors and use thereof POLI, POLN, POLB PDE5A 1111/4885KMT2A 2315/4885PDE1A 2625/4885
US-10723741-B1 DNA polymerase IIIC inhibitors and use thereof POLI, POLN, POLB PDE5A 1152/4885KMT2A 2290/4885PDE1A 2568/4885
US-10836772-B2 DNA polymerase IIIC inhibitors and use thereof POLI, POLN, POLB PDE5A 1111/4885KMT2A 2315/4885PDE1A 2625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.